Investigational drug · Phase 3
SHR-1314
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
16
Any phase or sponsor naming "SHR-1314"
First trial start
2024
Nov 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1314", any sponsor or status.
Conditions studied
As listed on its trial records.
- Active Non-radiographic Axial Spondyloarthritis
- Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
- Psoriatic Arthritis
Approved drugs for the same conditions: Plaque psoriasis · Psoriatic arthritis · Ankylosing spondylitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1314" as an intervention, largest first.
- Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque PsoriasisPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04839016 · 660 participants (planned) · Start Apr 25, 2021 · Primary completion Aug 30, 2023
Drug: SHR-1314; Placebo · For: Moderate-to-Severe Plaque Psoriasis
- Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing SpondylitisPivotal-lookingCompleted
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT04840485 · 548 participants · Start Jun 9, 2021 · Primary completion Nov 3, 2023
Drug: SHR-1314; SHR-1314 and 1 more · For: Ankylosing Spondylitis
Sites: Beijing, China
- A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial SpondyloarthritisPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06860750 · 380 participants (planned) · Start Apr 29, 2025 · Primary completion Feb 2028
Drug: SHR-1314 Injection; SHR-1314 Placebo Injection · For: Active Non-radiographic Axial Spondyloarthritis
Sites: Beijing, China
- Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque PsoriasisPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03463187 · 211 participants · Start Dec 15, 2017 · Primary completion Aug 31, 2020
Drug: SHR-1314; Placebo · For: Moderate-to-severe Chronic Plaque Psoriasis
Sites: Phoenix, Arizona; Anaheim, California; Doral, Florida · 13 sites in all
- A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06640257 · 208 participants · Start Nov 4, 2024 · Primary completion Jun 5, 2026
Drug: SHR-1314 injection; Placebo · For: Psoriatic Arthritis
Sites: Shanghai, China
- A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy SubjectsPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04527484 · 130 participants (planned) · Start Aug 20, 2020 · Primary completion Jan 10, 2021
Drug: SHR-1314 · For: Bioequivalence
- A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in AdultsPivotal-lookingSuspended
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04121143 · 120 participants (planned) · Start Nov 9, 2019 · Primary completion Jun 30, 2020
Drug: IL-17A Antagonist; Placebos · For: Plaque Psoriasis
Sites: Shanghai, China
- Study of the Effectiveness and Safety of SHR-1314 for Psoriatic ArthritisPivotal-lookingCompleted
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT05055934 · 112 participants · Start Oct 22, 2021 · Primary completion Jun 5, 2024
Drug: SHR-1314 injection; placebo · For: Psoriatic Arthritis
Sites: Shanghai, China
- The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06833307 · 90 participants (planned) · Start Feb 2025 · Primary completion Jul 2026
Drug: SHR-1314 · For: Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
Sites: Beijing, China; Shanghai, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT04924296 · 60 participants (planned) · Start Jun 28, 2021 · Primary completion Dec 25, 2021
Drug: SHR-1314; Placebo · For: Lupus Nephritis
Newest research
PubMed records naming it or its code names, newest first.
- Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study.
Xue Y, Sun L, Zhang N, et al. · Rheumatology (Oxford) 2026
- Safety, pharmacokinetics, and bioequivalence of vunakizumab injection, a specific dermatitis drug, in healthy Chinese volunteers: an open-label, randomized, two-stage, two-sequence cross-over study.
Dong Y, Gao X, Feng S, et al. · Expert Opin Drug Metab Toxicol 2025
- Immunophenotype of Lacrimal Glands in Graves Orbitopathy: Implications for the Pathogenesis of Th1 and Th17 Immunity.
Huang Y, Wu Y, Zhang S, et al. · Thyroid 2022
- A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.
Zhang C, Yan K, Diao Q, et al. · J Am Acad Dermatol 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.